State of the Biomarker Science in Ovarian Cancer: A National Cancer Institute Clinical Trials Planning Meeting Report

By sjmartinez • October 19, 2022

Ethier JL, Fuh KC, Arend R, Konecny GE, Konstantinopoulos PA, Odunsi K, Swisher EM, Kohn EC, Zamarin D. State of the Biomarker Science in Ovarian Cancer: A National Cancer Institute Clinical Trials Planning Meeting Report. JCO Precis Oncol. 2022 Oct;6:e2200355. doi: 10.1200/PO.22.00355. PMID: 36240472.

Tags: Hematology/Oncology, Publications

Related Posts

Predictors of pathologic complete response in early-stage triple-negative breast cancer treated with neoadjuvant chemo-immunotherapy: a multi-institution study

LeVee A, Santos B, Wong M, Ruel N, Schmolze D, Kang I, Tsai K, Mortimer J, McArthur H. Predictors of pathologic complete response in early-stage[...]

Osimertinib plus selumetinib in patients with EGFR-mutated advanced NSCLC with BRAF alterations post-progression on first-line osimertinib: ORCHARD

Piotrowska Z, Goldberg SB, Goldman JW, de Langen AJ, Le X, Okamoto I, Riess JW, Yu HA, Nishino K, Novello S, Ponce S, Ambrose H,[...]

Integrative Surface Antigen Profiling of KLK2 and STEAP1 in Advanced Prostate Cancer

Sayar E, Richards HM, Gulati R, Patel RA, Hanratty B, Lee HJ, Coleman I, Mustafi P, Ding CC, Chen WS, Quigley D, Setty M, Lang[...]